05:01 AM EDT, 09/10/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Tuesday it dosed the first patient in its phase 3 BiPass study evaluating Illuccix and Gozellix for prostate cancer diagnosis.

The trial will test whether combining MRI with PSMA-PET imaging can reduce the need for invasive biopsies or limit patients to a single precision biopsy, the company said.

Enrollment will include 204 men in Australia and the US, with the first patient treated at the Australian Prostate Centre and Melbourne Theranostic Innovation Centre, Telix said.

The study aims to build on prior research showing MRI plus PSMA-PET improves detection accuracy and could expand the US market for Telix's imaging agents by about 800,000 scans, the company added.

Shares of the company were up over 3.7% in recent Wednesday premarket activity.